Medication info

Pregabalin Capsule 25 mg (Pregabalin)

Prescription medicationApproval withdrawn
Ingredient · strength
Pregabalin›Strength being verified
Manufacturer / importer
Cosmax Pharma Co., Ltd.
Appearance
A hard capsule with a pale yellow upper part and white lower part containing a white powder that is white or light yellow.
Packaging
30 capsules per bottle
Approval status
Approval withdrawn

MFDS item code 201901230 · Approved 2019.02.26

This product's status changed to Approval withdrawn on 2023.07.19. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of epilepsy (partial seizures)
Who uses it
Adults · Children
Adult dosage
Administer the total daily dose of this medicine, as pregabalin, orally in 2 divided doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see section 5, “Patients with Renal Impairment”). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150mg daily. Depending on the response and tolerability of the individual patient, the dose may be increased to 300mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600mg daily. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150mg daily. Depending on the response and tolerability of the individual patient, the dose may be increased to 300mg daily after 1 week. After an additional week, it may be increased to the target dose of 600mg daily. If the target daily dose is not tolerated, dose reduction may be considered (see section 4, “Discontinuation”). 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150mg daily. Depending on the response and tolerability of the individual patient, the dose may be increased to 300mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300mg–450mg daily. The initial dose is 75mg twice daily (150mg daily), and based on efficacy and tolerability, it may be increased within 1 week to 150mg twice daily (300mg daily). For patients who do not experience sufficient benefit at a dose of 300mg daily, the dose may be increased within 1 week to 225mg twice daily (450mg daily). Clinical studies have also been conducted with a dose of 600mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450mg daily are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted unchanged by the kidneys. Since clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function ≥60 (mL/min): Starting dose (mg/day) 150, maximum dose (mg/day) 600, BID or TID ≥30 -<60: Starting dose (mg/day) 75, maximum dose (mg/day) 300, BID or TID ≥15 -<30: Starting dose (mg/day) 25-50, maximum dose (mg/day) 150, QD or BID <15: Starting dose (mg/day) 25, maximum dose (mg/day) 75, QD Supplemental dose after hemodialysis: 25 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: A supplemental dose means an additional dose administered as a single dose. 6. Patients with hepatic impairment No dosage adjustment is needed in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.
Children's dosage
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12–17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Cosmax Pharma Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of epilepsy (partial seizures)

  • Peripheral neuropathic pain
  • central neuropathic pain
  • epilepsy
  • partial seizures
  • fibromyalgia.
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. It is also utilized as an adjunct for partial seizures, with or without secondary generalization, in epilepsy patients. Additionally, it is effective in treating fibromyalgia. It aids in alleviating major neurological pain, seizures, and musculoskeletal symptoms, thereby improving the quality of life for patients.

Dosage and Administration

Adult dosage

Administer the total daily dose of this medicine, as pregabalin, orally in 2 divided doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see section 5, “Patients with Renal Impairment”). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150mg daily. Depending on the response and tolerability of the individual patient, the dose may be increased to 300mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600mg daily. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150mg daily. Depending on the response and tolerability of the individual patient, the dose may be increased to 300mg daily after 1 week. After an additional week, it may be increased to the target dose of 600mg daily. If the target daily dose is not tolerated, dose reduction may be considered (see section 4, “Discontinuation”). 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150mg daily. Depending on the response and tolerability of the individual patient, the dose may be increased to 300mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300mg–450mg daily. The initial dose is 75mg twice daily (150mg daily), and based on efficacy and tolerability, it may be increased within 1 week to 150mg twice daily (300mg daily). For patients who do not experience sufficient benefit at a dose of 300mg daily, the dose may be increased within 1 week to 225mg twice daily (450mg daily). Clinical studies have also been conducted with a dose of 600mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450mg daily are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted unchanged by the kidneys. Since clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function ≥60 (mL/min): Starting dose (mg/day) 150, maximum dose (mg/day) 600, BID or TID ≥30 -<60: Starting dose (mg/day) 75, maximum dose (mg/day) 300, BID or TID ≥15 -<30: Starting dose (mg/day) 25-50, maximum dose (mg/day) 150, QD or BID <15: Starting dose (mg/day) 25, maximum dose (mg/day) 75, QD Supplemental dose after hemodialysis: 25 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: A supplemental dose means an additional dose administered as a single dose. 6. Patients with hepatic impairment No dosage adjustment is needed in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.

Children's dosage

Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12–17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behavior, thus mood or behavior changes should be closely monitored during use. Patients with hypersensitivity to this medication or with genetically determined lactose intolerance should not take it. Diabetic patients should be aware that weight gain may affect blood sugar control. Immediate discontinuation of the medication is necessary if serious allergic reactions such as angioedema occur. Elderly patients should be cautious due to risks of dizziness or drowsiness, which may lead to injuries, and may experience vision changes such as blurred vision. Discontinuing this medication suddenly can result in withdrawal symptoms such as insomnia, headaches, or anxiety, and should be tapered off gradually under medical guidance. Due to the potential for drug abuse or dependence, patients must inform healthcare providers of their mental health status and history of drug use. Patients with impaired renal function may require dosage adjustments. Patients with heart disease should take this medication with caution. Due to its central nervous system depressant effects, there may be increased risk of respiratory depression when used with opioids or other depressants. During early pregnancy, there is a risk of fetal malformations; therefore, women who are pregnant or planning to become pregnant must consult their healthcare provider and use effective contraception. Breastfeeding women should discuss with their doctor whether to discontinue breastfeeding or the medication since it may be passed into breast milk. Risky activities such as driving or operating machinery should be avoided until the dizziness or drowsiness from the medication has resolved. In the event of severe skin reactions, the medication should be immediately discontinued, and healthcare providers should be notified. In case of overdose, immediate hospital care is required, and blood dialysis may be performed if needed. This medication should be stored out of reach of children, and should not be transferred to other containers for safety.

Side effects

  • suicidal ideation
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • periorbital edema
  • upper airway edema
  • dizziness
  • drowsiness
Show 200 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • sadness
  • pain
  • sweating
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • depression
  • euphoria
  • difficulty finding appropriate terms
  • hallucination
  • abnormal dreams
  • increased libido
  • panic attack
  • loss of inhibition
  • apathy
  • dizziness
  • drowsiness
  • ataxia
  • motor coordination disorders
  • balance disorders
  • amnesia
  • attention deficit
  • memory impairment
  • tremor
  • dysarthria
  • sensory abnormalities
  • sensory loss
  • sedation
  • hypersomnia
  • cognitive impairment
  • nystagmus
  • speech disorder
  • clonic contraction
  • decreased reflexes
  • motor abnormalities
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • intention tremor
  • syncope
  • confusion
  • exercise intolerance
  • olfactory abnormalities
  • loss of taste
  • dysgraphia
  • blurred vision
  • diplopia
  • indirect vision loss
  • visual disturbances
  • visual field loss
  • photophobia
  • dry eyes
  • ocular swelling
  • decreased vision
  • eye pain
  • eye fatigue
  • increased tear production
  • eye irritation
  • mydriasis
  • during vibration
  • changes in depth perception of vision
  • strabismus
  • brightness of vision
  • dizziness
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasm
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle stiffness
  • rhabdomyolysis
  • urinary disturbances
  • urinary incontinence
  • decreased urine
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • breast discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • sensation of drunkenness
  • sensory abnormalities
  • fatigue
  • tightness in the chest
  • systemic edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • loss of consciousness
  • mental disorder
  • keratitis
  • congestive heart failure
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • facial swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • shock
  • anaphylaxis-like symptoms
  • skin and mucous membrane syndrome
  • erythema multiforme
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • confusion
  • depression
  • agitation
  • restlessness
  • seizures

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent air and moisture ingress, preferably in a cool place between 15 and 30 degrees Celsius. Storing it this way will help maintain its effectiveness over time.

Appearance and packaging

Appearance

A hard capsule with a pale yellow upper part and white lower part containing a white powder that is white or light yellow.

Package unit

30 capsules per bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.